Vanguard Group
LENZ

Vanguard Group’s LENZ Therapeutics LENZ Stock Holding History

Vanguard Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$21.1M Sell
1,321,202
-9,084
-0.7% -$265K ﹤0.01% 2596
2025
Q3 		$62M Buy
1,330,286
+39,292
+3% +$1.44M ﹤0.01% 2057
2025
Q2 		$37.8M Buy
1,290,994
+91,532
+8% +$2.49M ﹤0.01% 2251
2025
Q1 		$30.8M Buy
1,199,462
+21,015
+2% +$518K ﹤0.01% 2305
2024
Q4 		$34M Buy
1,178,447
+59,630
+5% +$1.82M ﹤0.01% 2326
2024
Q3 		$26.6M Buy
1,118,817
+162,510
+17% +$3.61M ﹤0.01% 2457
2024
Q2 		$16.5M Buy
956,307
+749,355
+362% +$13.1M ﹤0.01% 2655
2024
Q1 		$4.62M Buy
206,952
+3,241
+2% +$67.4K ﹤0.01% 3330
2023
Q4 		$3.74M Buy
203,711
+5,930
+3% +$97.9K ﹤0.01% 3394
2023
Q3 		$3.43M Buy
197,781
+689
+0.3% +$12K ﹤0.01% 3405
2023
Q2 		$3.59M Buy
197,092
+20,744
+12% +$414K ﹤0.01% 3458
2023
Q1 		$3.02M Buy
176,348
+1,074
+0.6% +$17.4K ﹤0.01% 3524
2022
Q4 		$4.07M Buy
175,274
+3,805
+2% +$88.2K ﹤0.01% 3397
2022
Q3 		$3.81M Buy
171,469
+19,482
+13% +$464K ﹤0.01% 3462
2022
Q2 		$2.93M Sell
151,987
-19,835
-12% -$442K ﹤0.01% 3640
2022
Q1 		$6.13M Buy
171,822
+71,769
+72% +$4.49M ﹤0.01% 3426
2021
Q4 		$8.71M Buy
100,053
+563
+0.6% +$46.6K ﹤0.01% 3296
2021
Q3 		$11.4M Buy
99,490
+95,204
+2,221% +$14.1M ﹤0.01% 3161
2021
Q2 		$921K Buy
+4,286
New +$747K ﹤0.01% 4167

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group's LENZ Position: Q4 2025 in Review

Vanguard Group reduced its LENZ Therapeutics (LENZ) stake by 0.68% in Q4 2025, selling an estimated $265K and leaving 1,321,202 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

Vanguard Group first reported a position in LENZ in Q2 2021 and has held it in 19 quarters since. The position peaked at $62M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Vanguard Group held 1,321,202 shares of LENZ Therapeutics worth $21.1M as of Q4 2025.
  • Vanguard Group sold 9,084 LENZ Therapeutics shares in Q4 2025, an estimated $265K.
  • LENZ Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2596 holding.
  • Vanguard Group first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Vanguard Group's LENZ Therapeutics position peaked at $62M in Q3 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.